About: SARS-CoV-2 in first trimester pregnancy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 in first trimester pregnancy - does it affect the fetus? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 in first trimester pregnancy - does it affect the fetus?
Creator	Ditte, Marie Bang, Professor, Assoc Astrid, Marie Bello-Rodríguez, Berntsen, Sine Christiansen, Ann-Marie Egerup, Pia Elin, Rosenbek Hoffmann, Eva Hviid, Römmelmayer Ingham, Jeppe Ethelberg-Findsen, Jørgensen, Finn Jørgensen, Henrik Kolte, La Cour Freiesleben, Nina Nielsen, Henriette Ollé-López, Joaquim Olsen, Line Praetorius, Lisbeth Reinhardt Nielsen, M Severinsen, Storm, Vauvert, Kathrine Westergaard, David Westh, Henrik Wilken-Jensen, Charlotte Zedeler, Anne
Source	MedRxiv
abstract	Background Several viral infections are known to be harmful to the fetus in the first trimester of pregnancy and can cause increased nuchal translucency thickness and pregnancy loss. Currently, no evidence exists regarding possible effects of SARS-CoV-2 in first trimester pregnancies. Methods Cohort 1 included pregnant women with a double test taken between Feb. 17 and Apr. 23, 2020, during the SARS-CoV-2 epidemic peak in Denmark. The double test was taken as part of the first trimester risk assessment. Cohort 2 included women with a first trimester pregnancy loss before double test. Serum from the double test or from a blood sample, in case of pregnancy loss, was analyzed for SARS-CoV-2 antibodies. The results were correlated to the nuchal translucency thickness and the number of pregnancy losses. Results In total, 1,019 pregnant women with double test and 36 women with pregnancy loss participated in the study. Thirty (2.9%) women had SARS-CoV-2 antibodies in the serum from the double test. All women with pregnancy loss prior to the double test were negative for SARS-CoV-2 antibodies. There were no significant differences in nuchal translucency thickness for women testing positive (n=14) versus negative (p=0.20) or grey zone (n=16) versus negative (p=0.28). In total, 54 women experienced a pregnancy loss of whom two had grey zone or positive SARS-CoV-2 antibodies. Conclusion Maternal SARS-CoV-2 infection did not seem harmful in first trimester pregnancies. Infection had no effect on the nuchal translucency thickness and women with SARS-CoV-2 antibodies were not overrepresented among women with pregnancy loss.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1101/2020.06.08.20125195
has license	medrxiv
sha1sum (hex)	3c0fa5d054c49345b15ef0571cbfda26c3b2f260
schema:url	https://doi.org/10.1101/2020.06.08.20125195
resource representing a document's title	SARS-CoV-2 in first trimester pregnancy - does it affect the fetus?
resource representing a document's body	covid:3c0fa5d054c49345b15ef0571cbfda26c3b2f260#body_text
is schema:about of	named entity 'INCREASED NUCHAL TRANSLUCENCY' named entity 'pregnancies' named entity 'trimester of pregnancy' named entity 'randomly selected' named entity 'IgM' named entity 'epidemics' named entity 'nuchal translucency' named entity 'positive test' named entity 'preprint' named entity 'preprint' named entity 'maternal-fetal transmission' named entity 'preprint' named entity 'PAPP-A' named entity 'pregnancy loss' named entity 'Denmark' named entity 'peer review' named entity 'infection' named entity 'Covid-19' named entity 'SARS-CoV-2' named entity 'β-hCG' named entity 'SARS-CoV-2' named entity 'pathogens' named entity 'IgM' named entity 'IgG' named entity 'fetus' named entity 'preprint' named entity 'Parvovirus B19 infection' named entity 'SARS-CoV-2' named entity 'nuchal translucency measurement' named entity 'preprint' named entity 'IgG' named entity 'Covid' named entity 'pregnant women' named entity 'infection' named entity 'β-hCG' named entity 'antibodies' named entity 'comorbidity' named entity 'asymptomatic' named entity 'antibodies' named entity 'epidemic' named entity 'SARS-CoV-2' named entity 'significant difference' named entity 'medical files' named entity 'IgM' named entity 'pregnant women' named entity 'preprint' named entity 'obstetric' named entity 'SARS-CoV-2' named entity 'Covid' named entity 'severe acute respiratory syndrome' named entity 'peer review' named entity 'serological testing' named entity 'pregnant women' named entity 'symptom' named entity 'work from home' named entity 'maternal age' named entity 'fatality rate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software